Gabapentin Capsule
Product Images NDC 60760-926

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-926). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

926-60 (Gabapentin 60760 926 60)

This text provides information about Gabapentin capsules in 100mg strength, with a quantity of 60 capsules per bottle. It includes details such as the NDC code, lot number, expiration date, manufacturing information, and storage instructions. It also mentions the pharmacy program associated with the product and emphasizes using the medication as directed. The text further advises storing the capsules at controlled room temperature between 15°-30°C (59°-86°F).*

FDA Label Image

Gaba-fig1 (Gaba Fig1)

This text seems to contain a pain evaluation chart detailing the mean pain scores during a study period involving dose titration and a fixed dose for a medication (Possibly Gabapentin). The pain scores are recorded from baseline to week 8. The study includes a placebo group and a group receiving 3600 mg/day of Gabapentin.*

FDA Label Image

Gaba-fig2 (Gaba Fig2)

This text appears to describe a study or clinical trial evaluating the pain score over a total of 7 weeks. The study involves a 3-week dose titration period followed by a 4-week fixed dose period. The pain scores are observed and compared for placebo, Gabapentin at 1800 mg/day, and Gabapentin at 2400 mg/day. The results seem to be presented graphically by plotting the mean pain score over the baseline and the 7 weeks of the study.*

FDA Label Image

Gaba-fig3 (Gaba Fig3)

This text appears to be a presentation of data from studies on controlled post-herpetic neuralgia (PHN) patients. It shows the proportion of responders (patients with a 50% reduction in pain score) at the endpoint of these studies. The data seems to highlight different response rates based on the dosage of GBP (Gabapentin) and the placebo (PBO) group. The study includes statistical significance markers (*P<0.01 and **P<0.001) denoting the level of significance for the reported results.*

FDA Label Image

Gaba-fig4 (Gaba Fig4)

FDA Label Image

Gaba-formula (Gaba Formula)

This text provides a formula to calculate creatinine clearance (CLCr) based on age, weight, and serum creatinine levels. The formula adjusts for gender by multiplying by 0.85 for female patients.*

FDA Label Image

Gaba-structure (Gaba Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.